Pipeline

  • IMC is developing a promising treatment for fibromyalgia, IBS, ME/CFS, and a broad range of other conditions that show strong evidence of sharing the same underlying pathophysiology. IMC has 9 potential compounds in the pipeline, 2 of which are highlighted below.

    IMC-1

    IMC’s lead compound is IMC-1, which has completed a successful phase 2 trial and has been granted a Fast Track Designation by the FDA for the treatment of fibromyalgia.

    IMC-1, a novel proprietary fixed dose combination medication, was studied to confirm the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence. IMC-1 is a combination anti-viral treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms.

    STAGE OF DEVELOPMENT DESCRIPTION COMPLETION
    OBSERVATIONAL FIELD EVIDENCE Combining and utilizing anti-viral compounds that consistently resulted in positive, sustained outcomes for patients
    Check
    PROOF-OF-CONCEPT ESTABLISHED The role of HSV-1 in chronic gastrointestinal disorders associated with fibromyalgia
    Check
    PROPRIETARY SCIENTIFIC PLATFORM Development of novel anti-viral compounds designed to inhibit replication and reactivation of the HSV-1 life cycle at different, critical stages
    Check
    PHASE 1 CLINICAL TRIAL N/A (application of pre-approved, established molecules)
    Check
    PHASE 2 CLINICAL TRIAL
    The "FAST" Study
    A study of IMC-1 In patients with fibromyalgia
    Check
    IMC-1 PHASE 3 CLINICAL TRIAL*
    NDA/ PRODUCT LABELING
    PHASE IV/
    POST-MARKETING SURVEILLANCE/PIPELINE


    *IMC is currently working with the FDA to meet all of the necessary requirements to start the IMC-1 phase 3 trials for the management of fibromyalgia.

    NRP-1

    IMC has its second novel product NRP-1, a proprietary throat spray designed to treat viral pharyngitis, a large unmet medical need and cause of most cases of pharyngitis. NRP-1 will also provide much needed relief for cancer patients undergoing head and neck radiation plagued with disabling oral mucositis/pharyngitis. This first-of-its-kind spray delivers the medication which then adheres to the posterior pharynx despite repeated swallows and saliva.